Product Description
Mechanisms of Action: ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hungary | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|